Evolus (EOLS) vs Indaptus Therapeutics (INDP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Indaptus Therapeutics (INDP) has outperformed Evolus (EOLS) over the past year, gaining 52.4% versus a loss of 4.8%. Over five years, EOLS leads with a +14.4% price change compared with -98.3% for INDP. Indaptus Therapeutics is the larger company by market cap ($433.2 million vs $431.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EOLS | INDP |
|---|---|---|
| Share price | $6.52 | $2.82 |
| Market cap | $431.55M | $433.16M |
| 1-day change | -6.86% | -9.90% |
| YTD return | -1.95% | -3.09% |
| 1-year return | -4.82% | +52.43% |
| 5-year return | +14.39% | -98.26% |
| Forward P/E | 22.68 | — |
| EPS (TTM) | $-0.48 | $-3.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $297.18M | — |
| Revenue growth (YoY) | +11.61% | — |
| Net income (latest FY) | $-51.64M | $-20.85M |
| Gross margin | 66.33% | — |
| Operating margin | -10.99% | — |
| Net margin | -17.38% | — |
| 52-week high | $9.31 | $5.96 |
| 52-week low | $3.86 | $0.92 |
| Distance from 52-week high | -29.97% | -52.68% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +136.20% | — |
| Average volume | 925.77K | 712.87K |
| Shares outstanding | 66.19M | 153.60M |
| Employees | 365 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INDP has outperformed EOLS by 57.2 percentage points over the past year.
About Evolus
EOLS stock →Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes.
Health Care · Biotechnology: Pharmaceutical Preparations · 365 employees
About Indaptus Therapeutics
INDP stock →Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
EOLS vs INDP FAQ
Which is bigger, Evolus or Indaptus Therapeutics?
Indaptus Therapeutics (INDP) is larger, with a market capitalization of $433.16M compared with $431.55M for Evolus (EOLS).
Which stock has performed better over the past year, EOLS or INDP?
INDP returned +52.43% over the past 12 months, compared with -4.82% for EOLS (price return, excluding dividends). Past performance does not predict future results.
Are Evolus and Indaptus Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.